Health Care • Biotechnology: Pharmaceutical Preparations
$14.05 ▼ -0.30
(-2.09%)
MKT CAP: $5.02B • VOL: 4.43M
52W L $2 52W H $24
ROARABLE / RQD
E • 33/100
PIOTROSKI
3 / 9
ERAS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $394.5M | $502.8M | $396.3M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$140.9M | -$179.6M | -$141.5M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$124.5M | -$161.7M | -$125.0M |
| EBITDA (Normalized) | -$140.8M | -$179.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$95.5M | -$109.4M | -$101.2M |
| Capital Expenditures (CapEx) | $128.0K | $60.0K | — |
| Free Cash Flow (FCF) | -$95.6M | -$109.5M | -$101.2M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -44.3% | -39.9% | — |
| Cash & Short-Term Equivalents | $73.8M | $67.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $325.2M | $423.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ERAS.